A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03275740 |
Recruitment Status :
Recruiting
First Posted : September 8, 2017
Last Update Posted : April 14, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Primary Immune Thrombocytopenia | Drug: PF-06755347 intravenous Drug: Placebo intravenous Drug: PF-06755347 subcutaneous Drug: Placebo subcutaneous | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 112 participants |
Allocation: | Randomized |
Intervention Model: | Sequential Assignment |
Intervention Model Description: | single ascending dose study |
Masking: | Double (Participant, Investigator) |
Masking Description: | Double blind (investigator and subject), sponsor open |
Primary Purpose: | Treatment |
Official Title: | A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, FIRST-IN-HUMAN TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF PF-06755347 AFTER SINGLE ASCENDING INTRAVENOUS AND SUBCUTANEOUS DOSING TO HEALTHY ADULT MALE PARTICIPANTS |
Actual Study Start Date : | July 17, 2017 |
Estimated Primary Completion Date : | June 3, 2022 |
Estimated Study Completion Date : | June 3, 2022 |

Arm | Intervention/treatment |
---|---|
Experimental: PF-06755347 intravenous
intravenous administration
|
Drug: PF-06755347 intravenous
Single doses of PF-06755347 will be administered intravenously dose levels 1, 2, 3, 4, 5, and 6. |
Placebo Comparator: Placebo intravenous
intravenous administration
|
Drug: Placebo intravenous
Placebo comparator |
Experimental: PF-06755347 subcutaneous
subcutaneous administration
|
Drug: PF-06755347 subcutaneous
single doses of PF-06755347 will be administered subcutaneously at dose levels of SC1, SC2, SC3, SC4, and SC5. |
Placebo Comparator: Placebo subcutaneous
subcutaneous administration
|
Drug: Placebo subcutaneous
placebo comparator |
- Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs) [ Time Frame: Baseline (study day -2) through study completion (study day 36 for intravenous dose cohorts 1 - 6, and study day 71 for subcutaneous dose cohorts 1 - 5 ]
- Number of Participants With Clinical Laboratory Abnormalities [ Time Frame: Baseline, study days 2, 4, 6, 8, 11, 15, 22, 29 and 36 for i.v. dose cohorts 1 - 6, and Baseline, study days 2, 3, 4, 6, 8, 11, 15, 22, 29, 36, 50 and day 71 for subcutaneous dose cohorts 1 - 5. ]Safety laboratory includes Hematology, Chemistry, Urinalysis, prothrombin time/international normalized ratio, partial thromboplastin time, D dimer, and fibrinogen
- Number of Participants With Categorical Vital Signs Data [ Time Frame: Baseline, study days 1, 2, 3, 4, 6, 8, 11, 15, 22, and day 36 for i.v. dose cohorts 1 - 6 and Baseline, study days 1, 2, 3, 4, 6, 8, 11, 15, 22, 29, 36, 50 and day 71 for subcutaneous dose cohorts 1 - 3. ]Vital signs include blood pressure, pulse rate, and oral body temperature. Number of participants with maximum increase from Baseline in sitting SBP and DBP of greater than or equal to 30 mmHg will be reported
- Number of Participants With Abnormal Electrocardiogram (ECG) [ Time Frame: Baseline (study day 1, pre-dose), study days 1 (post dose), 2, 4, 6, 8, 11, 22, 36 (end of study visit for intravenous dose cohorts 1 - 6, and end of study visit day 71 for subcutaneous dose cohorts 1 - 5 ]Criteria for ECG abnormalities: maximum PR interval >=300 milliseconds (msec) and maximum increase PR interval increase from baseline (IFB): percent change (Pctchg) >=25 percent (%) for baseline value of >200 msec and Pctchg>=50% for baseline value of <=200 msec for PR interval, maximum QRS interval >=140 msec and a maximum IFB: Pctchg>=50%, maximum QTCF interval (Fridericia's Correction) of 450 msec to <480 msec, 480 msec to <500 msec or >=500 msec and a maximum change of <=30change<60 or >=60 msec from baseline.
- Maximum Observed Plasma Concentration (Cmax) [ Time Frame: Baseline, 1, 3, 4, 5, 6, 8, 12 & 24 hours post dose for i.v. cohorts and baseline, 6 & 12 hours for subcutaneous cohorts. Study days 3, 4, 6, and 8 for i.v. dose cohorts 1-2, plus days 15, 22, 29, 36, 50 and 71 for i.v. cohorts 3 - 6 and subcu cohorts ]
- Dose Normalized Maximum Observed Plasma Concentration Cmax [ Time Frame: Baseline, 1, 3, 4, 5, 6, 8, 12 & 24 hours post dose for i.v. cohorts and baseline, 6 & 12 hours for subcu cohorts. Study days 3, 4, 6, and 8 for i.v. dose cohorts 1-2, plus days 15, 22, 29, 36, 50 and 71 for i.v. cohorts 3 - 6 and subcu cohorts ]
- Time to Reach Maximum Observed Plasma Concentration (Tmax) [ Time Frame: Baseline, 1, 3, 4, 5, 6, 8, 12 & 24 hours post dose for i.v. cohorts and baseline, 6 & 12 hours for subcutaneous cohorts. Study days 3, 4, 6, and 8 for i.v. dose cohorts 1-2, plus days 15, 22, 29, 36, 50 and 71 for i.v. cohorts 3 - 6 and subcu cohorts ]
- Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) [ Time Frame: Baseline, 1, 3, 4, 5, 6, 8, 12 & 24 hours post dose for i.v. cohorts and baseline, 6 & 12 hours for subcutaneous cohorts. Study days 3, 4, 6, and 8 for i.v. dose cohorts 1-2, plus days 15, 22, 29, 36, 50 and 71 for i.v. cohorts 3 - 6 and subcu cohorts ]Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)
- Dose Normalized Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) [ Time Frame: Baseline, 1, 3, 4, 5, 6, 8, 12 & 24 hours post dose for i.v. cohorts and baseline, 6 & 12 hours for subcu cohorts. Study days 3, 4, 6, and 8 for i.v. dose cohorts 1-2, plus days 15, 22, 29, 36, 50 and 71 for i.v. cohorts 3 - 6 and subcu cohorts ]
- Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) [ Time Frame: Baseline, 1, 3, 4, 5, 6, 8, 12 & 24 hours post dose for i.v. cohorts and baseline, 6 & 12 hours for subcu cohorts. Study days 3, 4, 6, and 8 for i.v. dose cohorts 1-2, plus days 15, 22, 29, 36, 50 and 71 for i.v. cohorts 3 - 6 and subcu cohorts ]AUCinf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC (0-t) plus AUC (t-inf).
- Dose Normalized Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) [ Time Frame: Baseline, 1, 3, 4, 5, 6, 8, 12 & 24 hours post dose for i.v. cohorts and baseline, 6 & 12 hours for subcu cohorts. Study days 3, 4, 6, and 8 for i.v. dose cohorts 1-2, plus days 15, 22, 29, 36, 50 and 71 for i.v. cohorts 3 - 6 and subcu cohorts ]
- Plasma Decay Half-Life (t1/2) [ Time Frame: Baseline, 1, 3, 4, 5, 6, 8, 12 & 24 hours post dose for i.v. cohorts and baseline, 6 & 12 hours for subcu cohorts. Study days 3, 4, 6, and 8 for i.v. dose cohorts 1-2, plus days 15, 22, 29, 36, 50 and 71 for i.v. cohorts 3 - 6 and subcu cohorts ]Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
- Apparent Clearance (CL) [ Time Frame: Baseline, 1, 3, 4, 5, 6, 8, 12 & 24 hours post dose for i.v. cohorts and baseline, 6 & 12 hours for subcu cohorts. Study days 3, 4, 6, and 8 for i.v. dose cohorts 1-2, plus days 15, 22, 29, 36, 50 and 71 for i.v. cohorts 3 - 6 and subcu cohorts ]Steady state total body clearance equals infusion rate (zero order) divided by steady state plasma concentration of study drug (R0/Css)
- Incidence of Anti-Drug Antibody (ADA) [ Time Frame: Baseline, study days 8, 15, and 36 for all dose cohorts plus day 71 for subcu cohorts ]
- Characterisation of biomarker changes [ Time Frame: Baseline (study day 1, pre-dose), 1, 3, 5, 8, and 24 hours post dose, study days 3, 4, 8, 15, and day 36 for i.v. cohorts and study day 71 for sub cu dose cohorts ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 55 Years (Adult) |
Sexes Eligible for Study: | Male |
Gender Based Eligibility: | Yes |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Healthy male participants who, at the time of screening, are between the ages of 18 and 55 years, inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including oral temperature, blood pressure (BP) and pulse rate measurement, pulse oximetry, 12 lead ECG or clinical laboratory tests.
- Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study.
- Chest X ray with no evidence of current, active tuberculosis (TB) or previous inactive TB, general infections, heart failure, malignancy, or other clinically significant abnormalities taken at Screening or within 3 months prior to Screening and read by a qualified radiologist.
Exclusion Criteria:
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
- Participants with a history of autoimmune disorders and other conditions that compromise or impair the immune system (including but not limited to: Crohns Disease, rheumatoid arthritis, scleroderma, systemic lupus erythematosus, Graves disease, and asthma) or have a current positive result for the following; rheumatoid factor, anti-nuclear antibody, or abnormal free triiodothyronine (T3), free thyroxine (T4), thyroid stimulating hormone (TSH), or thyroid stimulating antibody (TSAb) suggestive of thyroid disease.
Subjects with a history of allergic or anaphylactic reaction to any drug including immunoglobulin.
- History of active infections within 28 days prior to the screening visit.
- Subjects with a history of or current positive results for any of the following serological tests: Hepatitis B surface antigen (HepBsAg), Hepatitis B core antibody (HepBcAb), Hepatitis C antibody (HCVAb) or human immunodeficiency virus (HIV).
- Subjects with a history of thromboembolic events or current positive result for anti-cardiolipin antibody.
- History of TB or active, latent or inadequately treated TB infection. All positive TB test result(s) are exclusionary
- Male subjects with partners currently pregnant; male subjects able to father children who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03275740
Contact: Pfizer CT.gov Call Center | 1-800-718-1021 | ClinicalTrials.gov_Inquiries@pfizer.com |
United States, Connecticut | |
Pfizer New Haven Clinical Research Unit | Terminated |
New Haven, Connecticut, United States, 06511 | |
Belgium | |
Pfizer Clinical Research Unit | Active, not recruiting |
Brussels, Belgium, B-1070 | |
New Zealand | |
Christchurch Clinical Studies Trust Ltd | Recruiting |
Christchurch, New Zealand, 8011 | |
United Kingdom | |
Hammersmith Medicines Research (HMR) | Active, not recruiting |
London, United Kingdom, NW10 7EW |
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Responsible Party: | Pfizer |
ClinicalTrials.gov Identifier: | NCT03275740 |
Other Study ID Numbers: |
B7801001 2018-003315-21 ( EudraCT Number ) |
First Posted: | September 8, 2017 Key Record Dates |
Last Update Posted: | April 14, 2021 |
Last Verified: | April 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Plan Description: | Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests. |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Polyradiculoneuropathy Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Thrombocytopenia Purpura, Thrombocytopenic, Idiopathic Blood Platelet Disorders Hematologic Diseases Purpura, Thrombocytopenic Purpura Blood Coagulation Disorders Thrombotic Microangiopathies Hemorrhagic Disorders |
Autoimmune Diseases Immune System Diseases Hemorrhage Pathologic Processes Skin Manifestations Autoimmune Diseases of the Nervous System Nervous System Diseases Demyelinating Diseases Polyneuropathies Peripheral Nervous System Diseases Neuromuscular Diseases |